Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Other Non Operating Income (2017 - 2024)

Aclaris Therapeutics has reported Other Non Operating Income over the past 8 years, most recently at $1.9 million for Q2 2024.

  • Quarterly results put Other Non Operating Income at $1.9 million for Q2 2024, down 16.83% from a year ago — trailing twelve months through Jun 2024 was $8.4 million (up 31.29% YoY), and the annual figure for FY2023 was $8.5 million, up 188.83%.
  • Other Non Operating Income for Q2 2024 was $1.9 million at Aclaris Therapeutics, down from $2.0 million in the prior quarter.
  • Over the last five years, Other Non Operating Income for ACRS hit a ceiling of $2.3 million in Q3 2023 and a floor of -$851000.0 in Q3 2021.
  • Median Other Non Operating Income over the past 5 years was $320000.0 (2020), compared with a mean of $763722.2.
  • Biggest five-year swings in Other Non Operating Income: crashed 338.66% in 2021 and later soared 1522.47% in 2022.
  • Aclaris Therapeutics' Other Non Operating Income stood at -$219000.0 in 2020, then surged by 140.64% to $89000.0 in 2021, then skyrocketed by 1522.47% to $1.4 million in 2022, then skyrocketed by 51.59% to $2.2 million in 2023, then dropped by 14.66% to $1.9 million in 2024.
  • The last three reported values for Other Non Operating Income were $1.9 million (Q2 2024), $2.0 million (Q1 2024), and $2.2 million (Q4 2023) per Business Quant data.